Essential CGM Metrics: The Principal Dimensions of Glycemic Control in Diabetes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35714355/
Two essential metrics, treatment efficacy and treatment safety, are necessary and sufficient to characterize glycemic control in diabetes. Thus, quantitatively, diabetes treatment optimization is reduced to a 2-dimensional problem, meaning...
Conclusion: Two essential metrics, treatment efficacy and treatment safety, are necessary and sufficient to characterize glycemic control in diabetes. Thus, quantitatively, diabetes treatment optimization is reduced to a 2-dimensional problem, meaning that minimizing both exposure to hyperglycemia and risk for hypoglycemia will lead to...
Oral versus subcutaneous semaglutide for prevention of major adverse cardiovascular events: cost per outcome analysis of SUSTAIN-6 and PIONEER-6
Source : https://www.tandfonline.com/doi/abs/10.1080/00325481.2022.2090794?journalCode=ipgm20
ABSTRACT Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP1a), reduces the risk of major adverse cardiovascular events (MACE) in patients with Type 2 diabetes mellitus (T2DM). An oral version of semaglutide...
Conclusions: Oral and subcutaneous semaglutide prescribed to prevent MACE in patients with T2DM provide similar value for money. The choice between both therapies should be guided mainly by patient preferences.
Effectiveness, safety, and treatment adherence of biosimilar follow-on insulin in diabetes management - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35670655/
Aims: The purpose of this study was to assess the change in HbA 1c after initiation of biosimilar follow-on insulin (Basaglar) or reference insulin (Lantus) among patients with type 2...
Conclusions: In patients with type 2 diabetes, Basaglar provided similar glycemic control compared to Lantus, had similar safety profile and lower drug costs, and demonstrated more favorable adherence.
Blocking C3d+/GFAP+ A1 Astrocyte Conversion with Semaglutide Attenuates Blood-Brain Barrier Disruption in Mice after Ischemic Stroke
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116904/
Qi Zhang, 1 , # Chang Liu, 1 , # Rubing Shi, 1 Shiyi Zhou, 1 Huimin Shan, 1 Lidong Deng, 1 Tingting Chen, 1 Yiyan Guo, 1 Zhijun Zhang,...
Conclusion: We concluded that astrocytes undergo a phenotypic shift over time after ischemic stroke. C3d /GFAP astrocytes aggravate BBB disruption, suggesting that inhibiting C3d /GFAP astrocyte formation represents a novel strategy for the treatment of ischemic stroke.
The role of oral semaglutide in managing type 2 diabetes in Indian clinical settings: Addressing the unmet needs - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35653929/
Currently, there is no data available on oral semaglutide in Indian clinical settings. However, significant improvements in glycemic control, cardiac and renal benefits, as well as weight loss across clinical...
Conclusions: Currently, there is no data available on oral semaglutide in Indian clinical settings. However, significant improvements in glycemic control, cardiac and renal benefits, as well as weight loss across clinical trials should encourage clinicians to prioritize oral semaglutide over other antidiabetic agents.